These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24341609)

  • 1. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.
    Du X; Yang J; Ylipää A; Zhu Z
    J Hematol Oncol; 2013 Dec; 6():93. PubMed ID: 24341609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.
    Yang J; Ylipää A; Sun Y; Zheng H; Chen K; Nykter M; Trent J; Ratner N; Lev DC; Zhang W
    Clin Cancer Res; 2011 Dec; 17(24):7563-73. PubMed ID: 22042973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.
    Zhou W; Du X; Song F; Zheng H; Chen K; Zhang W; Yang J
    Oncotarget; 2016 Apr; 7(16):22234-44. PubMed ID: 26993773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Holtkamp N; Malzer E; Zietsch J; Okuducu AF; Mucha J; Mawrin C; Mautner VF; Schildhaus HU; von Deimling A
    Neuro Oncol; 2008 Dec; 10(6):946-57. PubMed ID: 18650488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decorin suppresses stemness and migration potential of malignant peripheral nerve sheath tumor through inhibiting epidermal growth factor receptor signaling.
    Jia X; Chen L; Yu C
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167181. PubMed ID: 38653361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor.
    Yu J; Deshmukh H; Payton JE; Dunham C; Scheithauer BW; Tihan T; Prayson RA; Guha A; Bridge JA; Ferner RE; Lindberg GM; Gutmann RJ; Emnett RJ; Salavaggione L; Gutmann DH; Nagarajan R; Watson MA; Perry A
    Clin Cancer Res; 2011 Apr; 17(7):1924-34. PubMed ID: 21325289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.
    Rahrmann EP; Moriarity BS; Otto GM; Watson AL; Choi K; Collins MH; Wallace M; Webber BR; Forster CL; Rizzardi AE; Schmechel SC; Ratner N; Largaespada DA
    Am J Pathol; 2014 Jul; 184(7):2082-98. PubMed ID: 24832557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
    Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
    Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
    Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
    Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray comparative genomic hybridization detection of copy number changes in desmoplastic melanoma and malignant peripheral nerve sheath tumor.
    Pryor JG; Brown-Kipphut BA; Iqbal A; Scott GA
    Am J Dermatopathol; 2011 Dec; 33(8):780-5. PubMed ID: 21785329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands.
    Byer SJ; Brossier NM; Peavler LT; Eckert JM; Watkins S; Roth KA; Carroll SL
    J Neuropathol Exp Neurol; 2013 Mar; 72(3):219-33. PubMed ID: 23399900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
    Dilworth JT; Wojtkowiak JW; Mathieu P; Tainsky MA; Reiners JJ; Mattingly RR; Hancock CN
    Cancer Biol Ther; 2008 Dec; 7(12):1938-46. PubMed ID: 18927496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
    Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M
    J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.
    Gong M; Ma J; Li M; Zhou M; Hock JM; Yu X
    Neuro Oncol; 2012 Aug; 14(8):1007-17. PubMed ID: 22718995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome.
    Skotheim RI; Kallioniemi A; Bjerkhagen B; Mertens F; Brekke HR; Monni O; Mousses S; Mandahl N; Soeter G; Nesland JM; Smeland S; Kallioniemi OP; Lothe RA
    J Clin Oncol; 2003 Dec; 21(24):4586-91. PubMed ID: 14673046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
    Suppiah S; Mansouri S; Mamatjan Y; Liu JC; Bhunia MM; Patil V; Rath P; Mehani B; Heir P; Bunda S; Velez-Reyes GL; Singh O; Ijad N; Pirouzmand N; Dalcourt T; Meng Y; Karimi S; Wei Q; Nassiri F; Pugh TJ; Bader GD; Aldape KD; Largaespada DA; Zadeh G
    Nat Commun; 2023 May; 14(1):2696. PubMed ID: 37164978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
    Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
    J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death.
    Qin W; Godec A; Zhang X; Zhu C; Shao J; Tao Y; Bu X; Hirbe AC
    Cancer Med; 2019 Sep; 8(11):5232-5241. PubMed ID: 31278855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms.
    Perry A; Kunz SN; Fuller CE; Banerjee R; Marley EF; Liapis H; Watson MA; Gutmann DH
    J Neuropathol Exp Neurol; 2002 Aug; 61(8):702-9. PubMed ID: 12152785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.